New hope for rare kidney disease? first human trial of CPV-104 begins
NCT ID NCT07483827
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests CPV-104, a new medicine designed to calm an overactive immune system part that attacks the kidneys in C3 glomerulopathy (C3G), a rare kidney disorder. It is the first time CPV-104 is given to people. The trial includes 39 participants: healthy volunteers receiving a single dose, and C3G patients receiving four weekly doses. The main goal is to check safety and how the body handles the drug, not yet whether it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CPV-104
What this could lead to
If safe, this could pave the way for a treatment that controls C3 glomerulopathy, a rare kidney disease with few options.
What could go wrong
This is a very early Phase 1 trial focused only on safety, not effectiveness. It is small (39 people) and may not lead to a working treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC Stichting
RECRUITINGAmsterdam, Netherlands
-
Centre Hospitalier Universitaire De Toulouse
RECRUITINGToulouse, France
-
Clinica Universidad De Navarra
RECRUITINGPamplona, Spain
-
Cliniques universitaires Saint-Luc
RECRUITINGBrussels, Belgium
-
Fakultni Thomayerova nemocnice
RECRUITINGPrague, Czechia
-
Fundacio Puigvert
NOT_YET_RECRUITINGBarcelona, Spain
-
Hospital Curry Cabral - Centro Hospitalar de Lisboa Central - ULS Sao José
RECRUITINGLisbon, Portugal
-
Hospital Universitario 12 De Octubre
RECRUITINGMadrid, Spain
-
Hospital Universitario Virgen De La Macarena
RECRUITINGSeville, Spain
-
Hôpital Européen Georges-Pompidou HEGP
NOT_YET_RECRUITINGParis, France
-
Karolinska University Hospital
RECRUITINGHuddinge, Sweden
-
Laiko General Hospital Of Athens
RECRUITINGAthens, Greece
-
Medizinische Universität Wien
RECRUITINGVienna, Austria
-
Pauls Stradins Clinical University Hospital
RECRUITINGRiga, Latvia
-
University Hospital Virgen Del Rocio S.L.
RECRUITINGSeville, Spain
-
Vilnius University Hospital Santaros Klinikos
RECRUITINGVilnius, Lithuania